Adjuvant therapy in node-negative breast cancer William L. McGuireMartin D. AbeloffC. Kent Osborne Viewpoints Pages: 97 - 115
Trilostane with hydrocortisone in treatment of metastatic breast cancer Ping S. ChuAman U. BuzdarGabriel N. Hortobagyi Report Pages: 117 - 121
Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases Ramón ColomerAlvaro RuibalLuis Salvador Report Pages: 123 - 133
Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer Jan C. BucknerJames N. IngleDelano M. Pfeifle Report Pages: 135 - 142
Risk factors and 10-year breast cancer survival in Northern Alberta Alan W. LeesHeather J. JenkinsJohn Hanson Report Pages: 143 - 151
Cell dissociation techniques in human breast cancer — Variations in tumor cell viability and DNA ploidy Britt-Marie LjungBrian MayallHelene S. Smith Report Pages: 153 - 159
Androgen and glucocorticoid receptor-mediated inhibition of cell proliferation by medroxyprogesterone acetate in ZR-75-1 human breast cancer cells Richard PoulinDenis BakerFernand Labrie Report Pages: 161 - 172
In vitro biotransformation of estradiol by explant cultures of murine mammary tissues Nitin T. TelangH. Leon BradlowMichael P. Osborne Report Pages: 173 - 181
Comment on ‘NCI Alert on node-negative breast cancer’ Murray H. Seltzer Correspondence Pages: 183 - 183